UK Biobank Ltd

1-2 Spectrum Way, Adswood

Stockport

SK3 0SA

UK

Person cyswllt: Andrea Howard

Ffôn: +44 1614755386

E-bost: andrea.howard@ukbiobank.ac.uk

NUTS: UKD3

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: http://www.ukbiobank.ac.uk

Cyfeiriad proffil y prynwr: https://www.mytenders.co.uk/search/Search_AuthProfile.aspx?ID=AA25607

II.1.1) Teitl

Procurement of Blood Collection Kits for the UK Biobank Study of Seroprevalence of Covid-19

Cyfeirnod: UKBB010

II.1.2) Prif god CPV

33141000

II.1.3) Y math o gontract

Cyflenwadau

II.1.4) Disgrifiad byr

UK Biobank (‘UKB’) is conducting a study of seroprevalence of Covid-19 in the population of up to 20 000 of its participants and their adult children and grandchildren (the ‘Study’). The study (which is funded for an initial period of 6 months by the Department of Health and Social Care) aims to collect blood samples from study participants each month for an initial period of 6 months and measure these samples to assess the extent of previous infection with the SARS CoV 2 coronavirus (by measuring blood antibodies) in different locations and age groups across the UK. In order to enable the Study, UKB needed a supplier to provide testing kits which could be mailed to study participants and safely returned to UKB’s laboratory in Cheadle before testing. There was an urgent need to secure supply of kits (which are globally in high demand) to enable the study to go ahead without delay. Med DX were identified as a supplier who were able to provide these kits to enable the Study to commence within the required urgent timeframe.

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.1.7) Cyfanswm gwerth y caffaeliad

Gwerth heb gynnwys TAW: 474 000.00 GBP

IV.1.1) Y math o weithdrefn

Dyfarnu contract heb gyhoeddi galwad am gystadleuaeth yng Nghyfnodolyn Swyddogol yr Undeb Ewropeaidd ymlaen llaw

Cyfiawnhau'r weithdrefn ddyfarnu a ddewiswyd:

Brys eithafol yn sgil digwyddiadau nad oedd modd i’r awdurdod contractio eu rhagweld ac yn unol â’r amodau llym a nodir yn y gyfarwyddeb

Esboniad

UKB has relied on Regulation 32(2)(c) of the Public Contracts Regulations 2015 to make a direct award due to extreme urgency. In relying on this ground UKB has considered the guidance set out in the Cabinet Office information note ‘Procurement Policy Note – Responding to Covid-19 Information Note PPN 01/20 (March 2020)’. The Covid-19 pandemic is so novel that the consequences were unforeseeable. Securing a supply of testing kits therefore became urgent given the current high global demand and limited supply, requiring UK Biobank to act with ‘extreme urgency’. Confirmation that the Study would be funded was only received on 23 April 2020. This urgency did not provide UKB with sufficient time to comply with the usual/accelerated timescales in the Public Contracts Regulations 2015. The urgency UKB is responding to could not have been foreseen and is not due to UKB’s delay in acting. Reliance on Regulation 32(2)(2)(c) was imperative to secure the commitment from a supplier as soon as possible as otherwise UKB could have lost the source of supply, resulting in the study being delayed. It was not practical to consider entering into a very short term supply contract whilst a competitive accelerated process was run for the remainder of the study as this would risk losing the source of future testing kits due to the very high global demand and limited supply.

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

MedDX

Unit 3, Skylon Place, Hursey Road

Rotherwas

HR2 6NX

UK

Ffôn: +44 1432850910

NUTS: UKG11

Cyfeiriad(au) rhyngrwyd

URL: http://www.meddxsolutions.co.uk/

BBaCh yw’r contractwr: Ydy

VI.4.1) Corff adolygu